• PDF: Delivered by email usually within 4 to 8 UK business hours.
  • PRINT/CD-ROM: Despatched within 1 to 2 working days.

Advancing Molecular Diagnostics to Personalize Cancer Therapy

  • Publication Date:June 2011
  • Publisher:Business Insights
  • Product Type: Report
  • Pages:187

Advancing Molecular Diagnostics to Personalize Cancer Therapy

Introduction

This report analyzes current and potential world markets for key cancer-based molecular diagnostics, including advances in the field. This report forecasts future growth to 2016. Market segments covered include: breast cancer; colon cancer; prostate cancer; non-small cell lung cancer; melanoma; and renal cancer. This report reviews the direction of research, and key issues facing the industry.

Features and benefits

  • Identify key innovations in molecular diagnostics for oncology that may compete with those in development at your company.
  • Understand the regulatory challenges facing the developers of molecular diagnostics for cancer.
  • Understand the challenges that surround successfully commercializing a combined drug-diagnostic product and learn how to overcome them.
  • Discover and analyze the key technology platforms being used in the development of novel molecular diagnostics.
  • Discover the forecast market size for key segments of the cancer diagnostics market including: breast, colorectal, prostate, lung, and renal cancer.

Highlights

Advances in genomics, proteomics, molecular imaging, and other new technologies are leading to a molecularly based reclassification of malignancy, creating market opportunities for diagnostic companies.

Companion diagnostics - linking drugs with diagnostics - is expected to become the prevailing health care model, offering advantages for both the prescription drug and diagnostics businesses. For diagnostics companies, combining with a successful companion drug can be a powerful driver of sales, especially when required for prescribing a drug.

If government regulatory agencies increase the use of biomarkers and diagnostics in prescribing decisions, it is likely that drug and diagnostics companies will increase their collaboration. New relationships are likely to develop between partners committed to personalized medicine embracing the approach of specialized pharmaceutical firms.

Your key questions answered

  • Which of the cancer diagnostic market segments are forecast to grow most rapidly through to 2016 and thus be the most commercially attractive?
  • What are the key innovations in molecular diagnostics that are going to drive market growth?
  • How can pharma and diagnostic companies work together to successfully develop combined drug and diagnostic products?
  • Which companies are developing the most promising technologies?
  • Executive Summary
    • Introduction
    • Trends in cancer diagnostics
    • Market developments
    • Market analysis
  • About the author
    • Disclaimer
  • Introduction
    • Summary
    • Perspective
      • Growing global incidence of cancer
      • The impact of unhealthy lifestyles on cancer
      • Personalized therapy gets closer
    • Molecularly targeted therapeutics
      • Move toward rationally designed trials
      • Accelerate the translation of preclinical research
    • Strategies toward personal cancer treatment
    • Near-term market opportunities
      • New pharmacogenomics, panels and arrays
      • Driving demand for tests
    • Drug-diagnostic co-development
      • Targeted drugs fueling diagnostic growth
      • Stratifying patients to the best treatment
  • Trends in cancer diagnostics
    • Summary
    • An evolving science
      • Demonstrating value
    • Evolving health care practices
      • Reducing time to market
      • Addressing regulatory concerns
      • Changing clinical practice
    • Diagnostic influences therapeutic molecule discovery
      • Identifying patient populations
    • Key platforms
      • PCR
      • Nucleic acid testing
      • Microfluidics
      • Gene expression profiling
      • Variety
    • The role of biomarkers
      • Prognostic
      • Predictive
      • Evaluating therapeutic activity
    • Challenges and issues
      • Commercializing theranostics
      • Regulatory challenges
      • Technical challenges
      • DTCs and CTCs
  • Market developments
    • Summary
    • New molecular test for cervical cancer
      • Detecting high risk types of HPV
    • License for EGFR lung cancer assay
    • Licensing agreement extended for prostate cancer biomarker
    • bioMérieux, GSK develop theranostic for treatment selection
    • Diagnostic test for pancreatic cancer
    • Test to select candidates for skin cancer immunotherapy
    • Collaboration for therapy, companion diagnostic
    • Companion diagnostics collaboration
    • Deal to accelerate development of new cancer diagnosis tools
    • Biomarkers for personalizing radiation cancer treatment
    • CTC antibodies on a chip track mesothelioma
    • Body fluid based oncology diagnostics
    • Highly validated genetic markers for malignant melanoma
    • Biomarkers for DNA methylation on melanoma tissue
    • Diagnostic predicts prostate cancer recurrence
    • Colorectal cancer test approved
  • Market analysis
    • Summary
    • Market drivers
      • Improving on prescription by trial and error
      • A need for more rapid, specific testing
    • Opportunities
      • Drug-diagnostic combinations
      • Rescuing failed drugs
      • An unmet need for improving diagnosis
    • Selected novel products on the market
      • HPV and cervical cancer
      • Multigene expression testing
      • Predicting risk of recurrence
      • Gene overexpression
      • KRAS mutations
      • Molecular classification
      • Mutation analysis
      • Drug resistance testing
      • Measuring exposure to drugs
    • World market analysis
      • Total solutions
      • Drug labeling modifications
      • Breast cancer
      • Colorectal cancer
      • Prostate cancer
      • Non-small cell lung cancer
      • Melanoma
      • Renal cancer
      • Market by type of diagnostic
  • Corporate Profiles
    • Abbott Molecular
      • Company description
    • Agendia
      • Company description
    • Allegro Diagnostics
      • Company description
    • Almac Group
      • Company description
    • AltheaDx
      • Company description
    • Asuragen
      • Company description
    • Atossa Genetics
      • Company description
    • AutoGenomics
      • Company description
    • Becton, Dickinson and Company
      • Company description
    • Biocartis SA
      • Company description
    • bioMérieux SA
      • Company description
    • Caris Life Sciences
      • Company description
    • CCC Diagnostics LLC
      • Company description
    • Cytocell Ltd.
      • Company description
    • Dako Denmark
      • Company description
    • deCODE genetics
      • Company description
    • Epigenomics AG
      • Company description
    • Exosome Diagnostics
      • Company description
    • Foundation Medicine
      • Company description
    • GE Healthcare
      • Company description
    • Gene Express
      • Company description
    • Genomic Health
      • Company description
    • Gen-Probe
      • Company description
    • Illumina
      • Company description
    • IncellDx
      • Company description
    • Innogenetics NV
      • Company description
    • InterGenetics
      • Company description
    • Ipsogen
      • Company description
    • Kreatech Diagnostics
      • Company description
    • MDxHealth
      • Company description
    • Myriad Genetics
      • Company description
    • Nanosphere
      • Company description
    • Oncohealth
      • Company description
    • On-Q-ity
      • Company description
    • Orion Genomics
      • Company description
    • Pathwork Diagnostics
      • Company description
    • Predictive Biosciences
      • Company description
    • Prometheus Laboratories
      • Company description
    • Qiagen
      • Company description
    • QuantaLife
      • Company description
    • Roche Molecular Diagnostics
      • Company description
    • Rosetta Genomics
      • Company description
    • Transgene
      • Company description
    • TrimGen
      • Company description
    • TrovaGene
      • Company description
    • Veridex
      • Company description
  • Appendix
    • Scope
    • Methodology
    • Glossary/Abbreviations
    • Bibliography/References
+44 20 8816 8548

Ask a question about Advancing Molecular Diagnostics to Personalize Cancer Therapy

Enter the characters you see in the picture below
Captcha